

## **Conference Abstracts**

1. Flerlage J, Feraco A, Zhou Y, **Zheng Y**, Jiang L, Lucas J, Friedmann A, Weinstein H, Yock T, Shulkin B, et al. Dose-dense chemotherapy enables elimination of radiotherapy for a majority of patients with low-risk pediatric Hodgkin lymphoma: a report on HOD08 from the Pediatric Hodgkin Consortium. *International Symposium on Hodgkin Lymphoma (ISHL13)*, October 26-28, 2024, Cologne, Germany.
2. Marks LJ, Zhou YW, **Zheng Y**, Feraco A, Friedmann A, Weinstein H, Link M, Flerlage J. Validation of Childhood Hodgkin International Prognostic Score (CHIPS) for Predicting Event-Free Survival in Intermediate and High-Risk Hodgkin Lymphoma. *The 65th ASH Annual Meeting and Exposition*. December 9-12, 2023, San Diego, California
3. Flerlage J, Castellino S, Furner B, Li M, Pei QL, Wu Y, Zhou YW, Zheng Y, Achen B, Graglia L, Henderson T, Hodgson D, Hoppe B, Kahn J, Kessel S. Data Collaborations Accelerate Pediatric Hodgkin Lymphoma Research Through NODAL. *International Symposium on Childhood, Adolescent, and Young Adult Hodgkin Lymphoma (ISCAYAHL)*, October 19-21, 2023, Memphis, Tennessee
4. Marks LJ, Zhou YW, **Zheng Y**, Feraco A, Friedmann A, Weinstein H, Link M, Flerlage J. Validation of Childhood Hodgkin International Prognostic Score (CHIPS) for Predicting Event-Free Survival in Intermediate and High-risk Hodgkin Lymphoma. *International Symposium on Childhood, Adolescent, and Young Adult Hodgkin Lymphoma (ISCAYAHL)*, October 19-21, 2023, Memphis, Tennessee
5. Friedmann A, Flerlage J, Weinstein H, Feraco A, Hudson M, Marks L, Dixon S, Lucas J, Ehrhardt M, Zhou YW, **Zheng Y**, Krasin M, Metzger M, Shulkin B, Kaste S, Donaldson S. Dose-dense chemotherapy for low-risk pediatric Hodgkin lymphoma enables de-escalation of radiotherapy: a report from the Pediatric Hodgkin Consortium. *International Symposium on Childhood, Adolescent, and Young Adult Hodgkin Lymphoma (ISCAYAHL)*, October 19-21, 2023, Memphis, Tennessee